EASL – International Liver Congress 2021

Published on 12/02/2021

23–26 June 2021
Digital congress

ENYO Pharma will be present from the 23th to the 26th of June 2021 at the digital EASL International Liver Congress with a first poster “A phase 2 study testing FXR agonist Vonafexor in treatment naive patients with chronic hepatitis B (CHB): preliminary week 16 results” (EASL-ICL 2021 Abstract No. 2844) in the Hepatitis B/D Therapy Session:

And a second poster “Farnesoid X receptor alpha ligands inhibit in vitro HDV replication and virion secretion and infectivity”

Read next in 'Events'

• The 2024 international workshop on Alport syndrome
• ENYO Pharma annonce un financement de Série C de 39 millions d'euros et l’autorisation de la FDA (IND) pour tester Vonafexor dans un essai clinique de Phase 2 pour les patients atteints du syndrome d'Alport
• 6th CKD Summit – Chronic Kidney Disease Drug Development
• ASN Kidney Week
• Alport Connect 2023, the annual Alport syndrome patient and family meeting in US